[ad_1]
Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) said the FDA has approved its drug Welireg for the treatment of advanced kidney cancer.
The product, also known as belzutifan, was approved for patients with advanced renal cell carcinoma following PD-1 or PD-1 inhibitor and a VEGF-TKI therapy. Welireg belongs to a newer class of therapeutics known as hypoxia-inducible factor-2 alpha inhibitors.
[ad_2]